Numab Therapeutics and Kaken Pharmaceutical Enter Collaboration and Option Agreement for Multi-specific Antibody ND081 for Treatment of Inflammatory Bowel Disease
15. November 2024 04:30 ET
|
Numab Therapeutics AG; Kaken Pharmaceutical Co., Ltd.
Numab to receive R&D funding for the preclinical development of ND081 Kaken Pharmaceutical receives an option to in-license ND081 in certain Asian territories in exchange for funding global...
CC Chemokine Receptor Type 5 Market Research Report 2024
07. November 2024 09:35 ET
|
Research and Markets
Dublin, Nov. 07, 2024 (GLOBE NEWSWIRE) -- The "CC Chemokine Receptor Type 5 Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The CC chemokine receptor type 5 market...
Numab Therapeutics Announces Initiation of Phase 1 Clinical Study of NM32 Program in Patients with Solid Tumors
30. Oktober 2024 08:00 ET
|
Numab Therapeutics AG
NM32 is a first-in-class half-life-enhanced T-cell engager targeting ROR1, a tumor associated antigen with broad expression in solid tumors and hematological malignancies Low molecular...
Australia & New Zealand Research Antibodies Market Report 2024-2030, with Leading Players Abcam, BD, Merck, Lonza, Cell Signaling Technology, F. Hoffmann-La Roche, Agilent Technologies, Revvity & More
14. Oktober 2024 07:41 ET
|
Research and Markets
Dublin, Oct. 14, 2024 (GLOBE NEWSWIRE) -- The "Australia & New Zealand Research Antibodies Market Size, Share and Trends Analysis Report by Product, Specificity, Technology, Source, Application,...
Diagonal Therapeutics to Present at the Cure HHT’s 15th International Scientific Conference
08. Oktober 2024 07:00 ET
|
DIAGONAL THERAPEUTICS, INC
Diagonal Therapeutics to Present at the Cure HHT’s 15th International Scientific Conference
IgG Mediated Autoimmune Diseases Biologic Drugs Research Report 2024: Humanized, Fully Human, Chimeric, Other Sources Insights and Forecasts 2019-2023 & 2024-2029
23. September 2024 07:07 ET
|
Research and Markets
Dublin, Sept. 23, 2024 (GLOBE NEWSWIRE) -- The "Global IgG Mediated Autoimmune Diseases Biologic Drugs Market (2024 Edition): Analysis By Antibody Source (Humanized, Fully Human, Chimeric, Other...
CD137 Antibodies Clinical Trials & Market Opportunity - Revolutionary CD137 Antibodies Poised to Transform Cancer Immunotherapy Landscape by 2027
12. September 2024 04:01 ET
|
Research and Markets
Dublin, Sept. 12, 2024 (GLOBE NEWSWIRE) -- The "CD137 Antibodies Clinical Trials & Market Opportunity Insight 2027" report has been added to ResearchAndMarkets.com's offering. CD137, also...
North America Rare Disease Therapeutics Market Size, Trends, Competition, Forecasts & Opportunities, 2019-2023 & 2024-2029
27. August 2024 09:27 ET
|
Research and Markets
Dublin, Aug. 27, 2024 (GLOBE NEWSWIRE) -- The "North America Rare Disease Therapeutics Market, By Country, Competition, Forecast & Opportunities, 2019-2029F" report has been added to ...
Biopharmaceuticals Global Business Report 2024 with Focus on 200+ Select Players Including Abbott, Amgen, Biogen, Eli Lilly and Co, F. Hoffmann-La Roche, J&J, Merck, Novo Nordisk, Pfizer, Sanofi
23. August 2024 07:20 ET
|
Research and Markets
Dublin, Aug. 23, 2024 (GLOBE NEWSWIRE) -- The "Biopharmaceuticals - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for...
Cancer Engineered Antibody Therapeutics Market Analysis 2024: Technology Advances and Increasing Interest from Tier I Pharmaceuticals Driving Growth of Engineered Antibodies
15. August 2024 07:35 ET
|
Research and Markets
Dublin, Aug. 15, 2024 (GLOBE NEWSWIRE) -- The "Engineered Antibody Therapeutics for Cancer" report has been added to ResearchAndMarkets.com's offering.This study analyzes the emergence of...